SCHEMBL3012633

SCHEMBL3012633

CCOC(=O)[C@H]1CCN(C(=O)OC(C)(C)C)C[C@@H]1c1ccc(OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
PDE4B Q07343 7/20 0.48
USP7 Q93009 2/20 0.47
STS P08842 1/20 0.46
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
MMP7 P09237 1/20 0.46
MMP9 P14780 1/20 0.46
GPR119 Q8TDV5 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012031 1.00 ALDH1A1 (0.50) ALDH1A1PDE4BUSP7STSMMP1
SCHEMBL7917974 1.00 ALDH1A1 (0.50) ALDH1A1PDE4BUSP7STSMMP1
SCHEMBL27097338 0.93 ALDH1A1 (0.54) ALDH1A1STSMMP1MMP3MMP7
SCHEMBL29450352 0.92 ALDH1A1 (0.50) ALDH1A1PDE4BSTSMMP1MMP3
SCHEMBL14920417 0.92 ALDH1A1 (0.50) ALDH1A1PDE4BSTSMMP1MMP3
SCHEMBL18586188 0.92 ALDH1A1 (0.50) ALDH1A1PDE4BSTSMMP1MMP3
SCHEMBL14920416 0.92 ALDH1A1 (0.50) ALDH1A1PDE4BSTSMMP1MMP3
SCHEMBL14934668 0.92 ALDH1A1 (0.50) ALDH1A1PDE4BSTSMMP1MMP3
SCHEMBL16141380 0.92 ALDH1A1 (0.50) ALDH1A1PDE4BSTSMMP1MMP3
SCHEMBL23060498 0.90 PDE4B (0.59) ALDH1A1PDE4BSTSMMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391615-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-01-16 EP disclosed
US-8324248-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2391615-A1 Piperidine derivatives as nk3 receptor antagonists F. Hoffmann-La Roche AG (CH) 2011-12-07 EP disclosed
US-20100197697-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-05 US disclosed
WO-2010086259-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197697-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS OPRK1, OPRM1, OPRL1 ALDH1A1 692/4885PDE4B 1062/4885USP7 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.